Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time digital monitoring of continuous bladder irrigation: clinical evaluation of a sensor-based system for hematuria and catheter-associated events.

Frontiers in digital health·2025
Same author

Long-term follow-up of "three horse shoe-like incision (3-HSI) holmium laser enucleation of the prostate: outcomes and efficacy of a novel en-bloc technique for anatomic transurethral prostatectomy".

BMC urology·2025
Same author

Multivariable regression analysis of perioperative parameters for a novel pulsed solid-state Thulium: YAG laser with high peak power versus Holmium: YAG laser in prostate enucleation.

World journal of urology·2025
Same author

Holmium laser enucleation of the prostate and strictures: long-term outcomes, stricture characteristics, and risk factors.

World journal of urology·2025
Same author

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Related Experiment Video

Updated: Jul 11, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

[Benign prostatic hyperplasia: medical therapy].

B Schlenker1, C Gratzke, P Weidlich

  • 1Klinik und Poliklinik für Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München. boris.schlenker@med.uni-muenchen.de

MMW Fortschritte Der Medizin
|October 5, 2007
PubMed
Summary
This summary is machine-generated.

Medical therapy for benign prostatic hyperplasia (BPH) aims to improve symptoms and prevent complications. Treatment is personalized, commonly using plant extracts, alpha-blockers, and 5-alpha reductase inhibitors.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) significantly impacts quality of life and can lead to severe complications.
  • Effective medical management is crucial for symptom relief and preventing disease progression.

Purpose of the Study:

  • To outline the primary and secondary goals of medical therapy for BPH.
  • To emphasize the importance of personalized treatment strategies.
  • To review commonly prescribed and emerging therapeutic agents.

Main Methods:

  • Review of current medical therapies for BPH.
  • Analysis of established and novel treatment options.
  • Discussion of individualized treatment approaches based on patient symptoms and progression risk.

Main Results:

  • Commonly prescribed BPH medications include plant extracts, alpha-blockers, and 5-alpha reductase inhibitors.
  • These therapies aim to improve urinary symptoms and quality of life.
  • Emerging evidence supports the use of antimuscarinic agents and phosphodiesterase type 5 inhibitors.

Conclusions:

  • Medical therapy for BPH should be tailored to individual patient needs.
  • Key goals include symptom improvement, quality of life enhancement, and prevention of complications like urinary retention and renal failure.
  • Novel therapeutic options show promise for BPH management.